Old Web
English
Sign In
Acemap
>
Paper
>
Cost-Utility of Idelalisib In Combination with Rituximab In Relapsed or Refractory Chronic Lymphocytic Leukemia
Cost-Utility of Idelalisib In Combination with Rituximab In Relapsed or Refractory Chronic Lymphocytic Leukemia
2017
Luis Felipe Casado
José Ángel Hernández
Isidro Jarque
María Echave
Miguel Ángel Casado
A. Castro Gómez
Keywords:
Oncology
Intensive care medicine
Rituximab
Internal medicine
Refractory Chronic Lymphocytic Leukemia
Idelalisib
Medicine
cost utility
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]